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We encountered a patient with infant botulism caused by a single clone of Clostridium botulinum type B. In
the early convalescent phase, a C. botulinum type B-like nontoxigenic organism emerged in the feces instead.
Growth inhibition of toxigenic strains by nontoxigenic strains was examined.
The clinical spectrum of infant botulism ranges widely, from
a symptomless state to severe paralysis (5). Treatment of symp-
tons is still a principle in the treatment of the disease (6), and
the mechanism of recovery remains unclear. We encountered
a 6-month-old patient with infant botulism caused by Clostrid-
ium botulinum type B, which was the first case of type B infant
botulism in Japan to be reported (3). In this patient, the caus-
ative type B organisms disappeared from the feces in early
recovery phase and nontoxigenic organisms indistinguishable
from the causative organisms emerged.
In brief, the patient’s symptoms started with constipation,
and neuromuscular illness characteristic of infant botulism was
observed on the 10th day from onset. On the 26th day from
onset, a gradual improvement in baseline function was ob-
served while mild constipation still continued. These symptoms
almost completely disappeared by the 43rd day. The route of
ingestion of the type B organism was unknown.
Fecal samples were obtained on the 10th, 26th, and 43rd
days from onset. The supernatant of the fecal suspension was
tested for lethal toxicity in mice. To isolate C. botulinum, the
fecal samples were spread on egg yolk-nutrient agar, which was
incubated anaerobically at 37°C for 2 days (9). The biological
and biochemical properties of the isolates were determined as
described previously (9).
Chromosomal DNAs were prepared from fecal isolates. Cul-
tures were grown in brain heart infusion (BHI; BBL, Becton
Dickinson Microbiology Systems, Cockeysville, Md.) contain-
ing 0.05% cysteine at 37°C for 5 h and were treated with
penicillin G before harvesting. The cells were heated at 70°C
for 10 min and were treated with lysozyme, sodium dodecyl
sulfate, and proteinase K. Chromosomal DNAs were prepared
from the lysate by phenol-chloroform extraction and RNase
treatment. The 5-mg DNA samples were digested with HindIII
or EcoRI and separated through a 1% agarose gel. The gel was
stained with ethidium bromide, and DNA fragments were vi-
sualized under UV light. To detect the type B neurotoxin gene,
the DNA fragments were transferred onto a nylon membrane
(7). The membrane was hybridized with a 32P-labelled DNA
probe for the type B toxin gene and autoradiographed. DNA
fragments for the probe were prepared by PCR with the primer
set B3 and B4 (8).
Botulinum type B toxicity values were 100 minimum lethal
doses (MLD)/g of feces obtained on the 10th day from onset
and 50 MLD/g of feces obtained on the 26th day. No toxicity in
feces obtained on the 43rd day was detected. Colonies char-
acteristic of proteolytic C. botulinum had developed on the
culture of feces obtained on the 10th day. Three strains, which
were randomly selected from the colonies, produced 4,000-
MLD/ml type B toxin in chopped-meat medium containing 1%
glucose (2, 9).
On the culture of feces obtained on the 26th day from onset,
colonies similar to those from feces obtained on the 10th day
had developed. However, none of 20 colonies randomly se-
lected was toxigenic. Six strains from these colonies were fur-
ther examined and showed the same biological and biochem-
ical properties as those of the three toxigenic strains (Table 1).
The restriction enzyme patterns of the chromosomal DNAs
from these nine strains were identical on the basis of visual
comparison (Fig. 1). Southern blot analysis of the EcoRI digest
showed that the toxigenic strains possessed a 15-kb fragment
containing the type B toxin gene and that the nontoxigenic
strains lost the fragment (Fig. 1). Colonies similar to proteo-
lytic C. botulinum were not found in feces obtained on the 43rd
day from onset.
To analyze the phenomenon of the toxigenic organisms dis-
appearing and the nontoxigenic organisms emerging in the
convalescent phase, three experiments concerning growth in-
hibition among all the toxigenic and nontoxigenic isolates were
performed. First, the toxigenic strains were cross-streaked
against the nontoxigenic strains on BHI agar and cultured.
Second, the actively growing toxigenic strains in BHI broth
were mixed with culture supernatants of the nontoxigenic
strains. No nontoxigenic strains inhibited growth of the toxi-
genic strains. Then, 1.8 3 108 cells of a toxigenic strain and
1.2 3 108 cells of a nontoxigenic strain (ratio, 1:0.67) were
cocultured in BHI broth overnight and five consecutive pas-
sages were performed. Then, the ratio of toxigenic cells to
nontoxigenic cells in the coculture was measured by colony
counting after plating. To distinguish toxigenic colonies from
nontoxigenic ones, the toxin gene was detected by PCR. The
final ratio was 1:0.81. A pure culture of the toxigenic strains did
not yield any nontoxigenic derivative after five consecutive
passages.
Analyses of the biochemical properties and restriction en-
zyme patterns of chromosomal DNAs suggest that the case we
report was caused by a single clone of a type B organism and
that the nontoxigenic strains might be derived from the toxi-
genic clone. It is also suggested that the toxigenic strains firmly
retain their toxigenicity in vitro. Therefore, it may be more
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likely that a small population of nontoxigenic organisms de-
rived from the toxigenic organism was ingested by the patient
with the toxigenic one. Since growth-inhibitory substances such
as bacteriocin (1, 4) were not found in the present study, it may
be supposed that another kind of interaction, such as compe-
tition in attachment to the intestinal surface, plays an impor-
tant role in the overgrowth of the nontoxigenic organisms
during the convalescent phase. Accumulated information gath-
ered from cases similar to the present case will lead to a better
understanding of the role of nontoxigenic organisms in infant
botulism.
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Liquefaction of 10% gelatin 1 1
Digestion of casein, milk, and meat 1 1
Volatile fatty acid from peptone-yeast extract-glucose medium A, ib, b, iv, and ica A or a, ib, B or b, iv, and ica
Indole production 2 2
Nitrate reduction 2 2
Acid production from arbutin, dextrin, glucose, glycerol, maltose, salicin,
sorbitol, starch, sucrose, and trehalose
1 1




NaCl tolerance (%) 4 4
Motility 1 1
a a, acetic acid; ib, isobutyric acid; b, n-butyric acid; iv, isovaleric acid; ic, isocaproic acid. Capital letters indicate at least 10 mM, and lowercase letters indicate less
than 10 mM. Isocaproic acid was detected in two toxigenic strains and in three nontoxigenic strains.
b Amygdalin, adonitol, arabinose, cellobiose, dulcitol, erythritol, fructose, galactose, glycogen, inositol, inulin, lactose, mannitol, mannose, melezitose, melibiose,
raffinose, rhamnose, ribose, sorbose, and xylose.
FIG. 1. Restriction enzyme patterns of chromosomal DNAs of the isolates
obtained from feces. (A) HindIII digestion; (B) EcoRI digestion; (C) Southern
blot analysis of the EcoRI digest with a probe specific to the type B neurotoxin
gene. Lanes: 1, marker; 2 to 4, the toxigenic strains; 5 to 10, the nontoxigenic
strains.
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